Program
anagliptin
Also written as “Anagliptin” and “SK-0403”.
Its studies are mostly in Diabetes Mellitus, Type 2, led by 3 companies.
Furthest: phase 4, since Jan 21, 20266 company-led studies, 1 open or runningNext primary completion: Mar 31, 2027 (phase 4)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| JW Pharmaceutical | 31 open or running | phase 4since Jan 21, 2026 | Feb 6, 2012 | Mar 31, 2027phase 4 · NCT07442006 |
| Kowa | 20 open or running | phase 2since Jul 22, 2010 | May 25, 2010 | none ahead |
| Sanwa Kagaku Kenkyusho | 10 open or running | phase 2since Sep 19, 2007 | Sep 19, 2007 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 19, 2007First study: phase 2 study in Diabetes Mellitus, Type 2New to Sanwa Kagaku KenkyushoSanwa Kagaku Kenkyusho · NCT00532506 · Japan
- May 25, 2010Kowa's first study: phase 1 study in Diabetes Mellitus, Type 2New to KowaKowa · NCT01131091 · 30 enrolled · United States
- Jul 22, 2010Phase 2 study in Diabetes Mellitus, Type 2Kowa · NCT01169090 · 620 enrolled · United States
- Feb 6, 2012JW Pharmaceutical's first studies: 2 phase 3 studies in Diabetes Mellitus, Type 2New to JW PharmaceuticalJW Pharmaceutical · NCT01529541, NCT01529528
- Jan 21, 2026Phase 4 study in Diabetes Mellitus, Type 2JW Pharmaceutical · NCT07442006 · 178 planned · South Korea
Ahead
- Mar 31, 2027Primary completion: phase 4 study in Diabetes Mellitus, Type 2JW Pharmaceutical · NCT07442006
TargetBeta
DPP4 →read by rule
“An orally available, potent, selective inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity”NCIt, by rule
“Dipeptidyl peptidase IV inhibitor”ChEMBL 37, by rule
Other programs on DPP4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sitagliptinrule | Merck | phase 4 | 123 |
| Linagliptinrule | Boehringer Ingelheim | phase 4 | 96 |
| gemigliptinrule | LG Chem | phase 4 | 30 |
| Empagliflozin/Linagliptinrule | Humanis Saglık Anonim Sirketi | phase 1 | 2 |
| cofrogliptinrule | Haisco Pharmaceutical Group | no phase | 1 |
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07442006Diabetes Mellitus, Type 2 · South Korea | 4 | Recruiting | JW Pharmaceutical | Mar 31, 2027 | 178 |
| NCT01529541Diabetes Mellitus, Type 2 · Korea, Republic of | 3 | Completed | JW Pharmaceutical | May 2013 | 200 |
| NCT01529528Diabetes Mellitus, Type 2 · South Korea | 3 | Completed | JW Pharmaceutical | Sep 2012 | 117 |
| NCT01169090Diabetes Mellitus, Type 2 · United States | 2 | Completed | Kowa | Jul 2011 | 620 |
| NCT01131091Diabetes Mellitus, Type 2 · United States | 1 | Completed | Kowa | Nov 2010 | 30 |
| NCT00532506Diabetes Mellitus, Type 2 · Japan | 2 | Completed | Sanwa Kagaku Kenkyusho |
How it is read
Names in the registry
- “Anagliptin”, 4 entries
- “SK-0403”, 3 entries
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.